Study Type Number ofPatients Therapy Stem cellsource DonorType Conditioningregimen SurvivalOutcomes Roos-Weil et al. [17] Retrospectiveregistry 34 Allo-SCT BM (56%)PBSC(26%) Cord blood(18%) Related(32%) Unrelated(68%) MAC* (73%)RIC (27%) OS (3-yr) 41%DFS (3-yr) 33% Tsagarakis et al.[21] Retrospectiveregistry 5 Allo-SCT NR NR NR OS (2-yr) 60% Aoki et al. [16] Retrospectiveregistry 25 Auto-SCTAllo-SCT BM (57%)PBSC (36%)Cord blood(7%) Related(50%) Unrelated(50%) Auto-SCTHigh-dose**Allo-SCTMAC*** (57%)RIC (43%) Auto-SCTOS (4-yr) 82%PFS (4-yr) 73%Allo-SCTOS (4-yr) 69%PFS (4-yr) 60% Heinicke et al.[15] Retrospectivesingle centre 3 Allo-SCT NR Related(0%) Unrelated(100%) MAC† (33%)RIC (67%) OS 18, 35, and 41months,respectively Dalle et al. [22] Retrospectiveregistry 9 Allo-SCT NR NR NR median OS21 months

Note: OS: overall survival, DFS: disease-free survival, PFS: progression free survival, allo-SCT: allogeneic stem cell transplant, auto-SCT: autologous stem cell transplant, NR: not reported *MAC (myeloablative conditioning) regimen defined as ≥8 Gy of total-body irradiation, ≥10 mg/kg of busulfan, or ≥150 mg/m2 of melphalan. All other regimens defined as RIC (reduced-intensity conditioning). **High-dose regimen included MCEC (ranimustine, carboplatin, etoposide, cyclophosphamide), MEAM (ranimustine, etoposide, cytarabine, melphalan), or total-body irradiation ***MAC regimen included total-body irradiation, cyclophosphamide, cytarabine, or busulphan. RIC regimen included fludarabine, busulphan, melphalan, total-body irradiation. †MAC regimen included total-body irradiation and etoposide. RIC regimen included fludarabine and thiotepa.

Table 2: Selected published data evaluating hematopoietic stem cell transplant in blastic plasmacytoid dendritic cell neoplasm.